Keros Therapeutics Inc represents a strong set of values and corporate philosophy. The company is dedicated to developing innovative therapies that address significant unmet needs in the field of rare diseases and cancer. Keros Therapeutics Inc prioritizes scientific rigor, collaboration, and patient-centricity in every aspect of their work. By leveraging their expertise and cutting-edge research, they aim to deliver transformative treatments that improve patients' lives. Keros Therapeutics Inc's commitment to excellence, integrity, and empathy drives their mission to make a lasting impact in the healthcare industry.

Keros Therapeutics Inc is primarily present in the United States.

Keros Therapeutics Inc has achieved several significant milestones in its history. The company successfully completed its initial public offering (IPO) in August 2020, raising approximately $96 million in gross proceeds. Additionally, Keros Therapeutics Inc has received numerous grants and awards for its innovative research and development efforts focused on novel protein therapeutic candidates. The company has also formed strategic collaborations with leading biopharmaceutical companies to advance its pipeline and expand its scientific capabilities. Notably, Keros Therapeutics Inc initiated a Phase 1 clinical trial for its lead candidate, KER-050, in May 2020, demonstrating its progress towards developing potentially groundbreaking treatments for blood disorders and other hematological conditions.

Keros Therapeutics Inc is a biotechnology company specialized in developing therapies for severe diseases. Founded in [year], the company focuses on researching and designing novel protein-targeted therapeutics. With a primary focus on modulating the transforming growth factor-beta (TGF-β) superfamily, Keros Therapeutics aims to address various medical conditions, including hematologic, musculoskeletal, fibrotic, and oncologic diseases. By leveraging its extensive expertise in protein science, medicinal chemistry, and computational biology, the company seeks to unlock innovative treatment options for patients in need. Keros Therapeutics Inc continues to drive advancements in biotechnology by designing and developing disease-modifying therapeutics with the potential to improve patient outcomes and quality of life.

The main competitors of Keros Therapeutics Inc in the market are other companies operating in the field of biopharmaceuticals, particularly those focusing on the development of therapeutics for hematological and musculoskeletal disorders. Some notable competitors include Amgen Inc, Gilead Sciences Inc, and Pfizer Inc. These companies share a similar market niche and are actively engaged in developing novel therapies to address unmet medical needs. However, Keros Therapeutics Inc distinguishes itself by its unique approach and innovative pipeline targeting specific diseases.

Keros Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

Keros Therapeutics Inc is a biotechnology company with a unique business model focused on the discovery and development of innovative therapeutics. The company utilizes its proprietary technology platform to leverage the understanding of protein structure and function in order to identify and target novel disease pathways. By targeting specific protein interactions, Keros Therapeutics aims to develop therapeutics for diseases with high unmet medical needs, including cancer, immunology, and genetic disorders. Through its research and development efforts, Keros Therapeutics Inc aims to bring transformative treatments to patients and create long-term value for its stakeholders.

P/E odnos Keros Therapeutics iznosi -9,09.

KUV kompanije Keros Therapeutics iznosi 748,62.

AlleAktien kvalitativni skor za Keros Therapeutics je 3/10.

očekivana Keros Therapeutics promet je 2,28 mil. USD.

Dobit očekivana Keros Therapeutics je -187,98 mil. USD.

Keros Therapeutics Inc. is a biopharmaceutical company focused on the development of small molecules for the treatment of serious diseases. The company utilizes its expertise in structural biology and chemistry to develop novel drugs with the potential to change lives.

Keros Therapeutics isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Keros Therapeutics trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Keros Therapeutics je US4923271013.

WKN od Keros Therapeutics je A2P2YF.

Oznaka za praćenje akcija kompanije Keros Therapeutics je KROS.

U poslednjih 12 meseci, Keros Therapeutics je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Keros Therapeutics će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Keros Therapeutics trenutno iznosi .

Keros Therapeutics isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Keros Therapeutics je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Keros Therapeutics se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Keros Therapeutics od 1. 11. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 1. 11. 2024..

Isplata poslednje dividende izvršena je 1. 11. 2024..

U godini 2023 kompanija Keros Therapeutics je isplatila 0 USD kao dividende.

Dividende od Keros Therapeutics se isplaćuju u USD.